Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone61-3-9639-6036
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$16.72 million
Profitability
Miscellaneous
Employees81
Next Earnings Date11/21/2019 (Estimated)
OptionableOptionable
Mesoblast (NASDAQ:MESO) Frequently Asked Questions
What is Mesoblast's stock symbol?
Mesoblast trades on the NASDAQ under the ticker symbol "MESO."
How were Mesoblast's earnings last quarter?
Mesoblast limited (NASDAQ:MESO) released its quarterly earnings results on Thursday, August, 29th. The company reported ($0.21) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.23) by $0.02. The company earned $1.97 million during the quarter, compared to analysts' expectations of $1.31 million. Mesoblast had a negative net margin of 536.97% and a negative return on equity of 17.66%. View Mesoblast's Earnings History.
When is Mesoblast's next earnings date?
What price target have analysts set for MESO?
5 analysts have issued 12-month price objectives for Mesoblast's shares. Their forecasts range from $6.00 to $23.00. On average, they anticipate Mesoblast's share price to reach $12.40 in the next twelve months. This suggests a possible upside of 100.3% from the stock's current price. View Analyst Price Targets for Mesoblast.
What is the consensus analysts' recommendation for Mesoblast?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mesoblast in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mesoblast.
What are Wall Street analysts saying about Mesoblast stock?
Here are some recent quotes from research analysts about Mesoblast stock:
- 1. According to Zacks Investment Research, "Mesoblast Limited is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast's allogeneic, 'off-the-shelf' cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions. " (10/2/2019)
- 2. Maxim Group analysts commented, "Mesoblast announced that it has expanded its collaboration with TEMCELL (AKA remestemcel-L ex-Japan) commercialization partner JCR Pharmaceuticals (4552 – NR) for a second time, with the addition of neonatal hypoxic ischemic encephalopathy (HIE)." (6/12/2019)
Has Mesoblast been receiving favorable news coverage?
Press coverage about MESO stock has been trending negative this week, according to InfoTrie. The research group ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Mesoblast earned a news impact score of -2.6 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Mesoblast.
Who are some of Mesoblast's key competitors?
Some companies that are related to Mesoblast include Halozyme Therapeutics (HALO), Iovance Biotherapeutics (IOVA), Acceleron Pharma (XLRN), Crispr Therapeutics (CRSP), Denali Therapeutics (DNLI), Regenxbio (RGNX), Coherus Biosciences (CHRS), Momenta Pharmaceuticals (MNTA), Audentes Therapeutics (BOLD), Orchard Therapeutics (ORTX), Alector (ALEC), Editas Medicine (EDIT), Sangamo Therapeutics (SGMO), Fate Therapeutics (FATE) and Aerie Pharmaceuticals (AERI).
What other stocks do shareholders of Mesoblast own?
Who are Mesoblast's key executives?
Mesoblast's management team includes the folowing people:
- Dr. Silviu Itescu, Founder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director (Age 62)
- Dr. Donna L. Skerrett, Chief Medical Officer (Age 62)
- Mr. Roger D. Brown BA, Head of Spinal Orthopedic Disorders
- Mr. Michael Schuster MS, BSc, MBA, Head of Pharma Partnering (Age 42)
- Dr. Kenneth M. Borow M.D., Exec. (Age 71)
When did Mesoblast IPO?
(MESO) raised $69 million in an initial public offering on Friday, November 13th 2015. The company issued 5,700,000 shares at a price of $12.10 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Maxim Group and Ladenburg Thalmann were co-managers.
How do I buy shares of Mesoblast?
Shares of MESO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Mesoblast's stock price today?
One share of MESO stock can currently be purchased for approximately $6.19.
How big of a company is Mesoblast?
Mesoblast has a market capitalization of $617.33 million and generates $16.72 million in revenue each year. The company earns $-89,800,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. Mesoblast employs 81 workers across the globe.View Additional Information About Mesoblast.
What is Mesoblast's official website?
How can I contact Mesoblast?
Mesoblast's mailing address is LEVEL 38 55 COLLINS STREET, MELBOURNE C3, 3000. The company can be reached via phone at 61-3-9639-6036 or via email at [email protected]
MarketBeat Community Rating for Mesoblast (NASDAQ MESO)
MarketBeat's community ratings are surveys of what our community members think about Mesoblast and other stocks. Vote "Outperform" if you believe MESO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MESO will underperform the S&P 500 over the long term. You may vote once every thirty days.
